Relmada Therapeutics, Inc. RLMD Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount
Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount at other companies
Other financials
Where this comes from
Reported directly by Relmada Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate.
The official record: Relmada Therapeutics, Inc.’s 10-K, filed March 19, 2026, on SEC EDGAR. View the filing →
Ask your AI about Relmada Therapeutics, Inc.'s effective income tax rate reconciliation at federal statutory income tax rate, amount.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Relmada Therapeutics, Inc.'s effective income tax rate reconciliation at federal statutory income tax rate, amount?
- Relmada Therapeutics, Inc. (RLMD) reported effective income tax rate reconciliation at federal statutory income tax rate, amount of -$3.01M in Q4 2025.
- What does effective income tax rate reconciliation at federal statutory income tax rate, amount mean?
- The theoretical income tax expense or benefit calculated by applying the standard U.S. federal statutory corporate tax rate to the company's pre-tax income or loss. It serves as the baseline for reconciling the actual effective tax rate against statutory requirements.